• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.

作者信息

Chang Anne Lynn S, Kim Jinah, Luciano Richard, Sullivan-Chang Loretta, Colevas Alexander D

机构信息

Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

Department of Dermatology, Stanford University School of Medicine, Redwood City, California2Department of Pathology, Stanford University School of Medicine, Palo Alto, California.

出版信息

JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705.

DOI:10.1001/jamadermatol.2015.2705
PMID:26422398
Abstract
摘要

相似文献

1
A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.一例对程序性细胞死亡蛋白1抑制剂帕博利珠单抗敏感的不可切除皮肤鳞状细胞癌病例报告
JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705.
2
Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.程序性细胞死亡蛋白1抑制剂治疗皮肤鳞状细胞癌的随访
JAMA Dermatol. 2017 Jan 1;153(1):92-94. doi: 10.1001/jamadermatol.2016.3884.
3
Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.III期转移性皮肤鳞状细胞癌对程序性死亡-1抑制剂帕博利珠单抗的反应模式及获得性耐药
Dermatol Ther. 2019 Nov;32(6):e13107. doi: 10.1111/dth.13107. Epub 2019 Oct 21.
4
Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.抗程序性细胞死亡蛋白1抑制剂用于晚期皮肤鳞状细胞癌和基底鳞状细胞癌的挽救治疗：5例初步经验
Br J Dermatol. 2016 Dec;175(6):1382-1386. doi: 10.1111/bjd.14642. Epub 2016 Oct 17.
5
Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.非黑色素瘤皮肤癌中的抗程序性细胞死亡-1疗法。
Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17.
6
Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.程序性细胞死亡配体在皮肤鳞状细胞癌中的表达及帕博利珠单抗治疗局部晚期疾病。
JAMA Dermatol. 2017 Apr 1;153(4):299-303. doi: 10.1001/jamadermatol.2016.5118.
7
Pembrolizumab for the treatment of melanoma.帕博利珠单抗用于治疗黑色素瘤。
Expert Rev Clin Pharmacol. 2015;8(5):515-27. doi: 10.1586/17512433.2015.1061430. Epub 2015 Jul 9.
8
Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.帕博利珠单抗治疗不可切除的皮肤鳞状细胞癌
BMJ Case Rep. 2019 Aug 2;12(8):e229915. doi: 10.1136/bcr-2019-229915.
9
Multiple keratin granulomata: A potential histologic clue to cutaneous squamous cell carcinoma responding to programmed cell death protein 1 inhibitor therapy.多发性角质形成细胞肉芽肿：皮肤鳞状细胞癌对程序性细胞死亡蛋白1抑制剂治疗有反应的潜在组织学线索。
J Cutan Pathol. 2019 Jun;46(6):452-454. doi: 10.1111/cup.13447. Epub 2019 Apr 4.
10
PD-1 Blockers.PD-1 抑制剂。
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.

引用本文的文献

1
Unresectable squamous cell carcinoma in a patient with spina bifida.脊髓裂患者的不可切除鳞状细胞癌。
BMJ Case Rep. 2024 Sep 28;17(9):e259682. doi: 10.1136/bcr-2024-259682.
2
Advances in cutaneous squamous cell carcinoma.皮肤鳞状细胞癌的研究进展。
Nat Rev Cancer. 2023 Jul;23(7):430-449. doi: 10.1038/s41568-023-00583-5. Epub 2023 Jun 7.
3
Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma.头颈部鳞状细胞癌的新辅助免疫疗法：期待其在颞骨鳞状细胞癌中的应用。
Curr Med Sci. 2023 Apr;43(2):213-222. doi: 10.1007/s11596-023-2700-2. Epub 2023 Mar 26.
4
The State of the Art of Radiotherapy for Non-melanoma Skin Cancer: A Review of the Literature.非黑色素瘤皮肤癌放射治疗的现状：文献综述
Front Med (Lausanne). 2022 Jun 27;9:913269. doi: 10.3389/fmed.2022.913269. eCollection 2022.
5
Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma.PD-L1 表达与高危皮肤鳞状细胞癌和基底细胞癌预后因素的关系。
Bosn J Basic Med Sci. 2022 Oct 23;22(6):894-900. doi: 10.17305/bjbms.2022.7574.
6
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.非黑色素瘤皮肤癌患者中免疫治疗候选者的识别：反应潜在预测因素综述
J Clin Med. 2022 Jun 11;11(12):3364. doi: 10.3390/jcm11123364.
7
Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.非黑色素瘤皮肤癌中的免疫检查点抑制：当前证据综述
Front Oncol. 2021 Dec 20;11:734354. doi: 10.3389/fonc.2021.734354. eCollection 2021.
8
Investigative Landscape in Advanced Non-Melanoma Skin Cancers.晚期非黑素瘤皮肤癌的研究现状。
Curr Treat Options Oncol. 2021 Jun 7;22(7):56. doi: 10.1007/s11864-021-00853-0.
9
Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma.局部精氨酸酶抑制可抑制皮肤鳞状细胞癌的生长。
Sci Rep. 2021 May 24;11(1):10731. doi: 10.1038/s41598-021-90200-y.
10
Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?免疫检查点阻断在晚期皮肤鳞状细胞癌中的应用：2020 年我们对此了解多少？
Int J Mol Sci. 2020 Dec 6;21(23):9300. doi: 10.3390/ijms21239300.